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S U M M A R Y
Genital warts caused by human papillomavirus (HPV) are the most frequent sexually transmitted
infection. We describe a case of severe perianal and genital HPV infection in a patient with acquired
aplastic anemia, unresponsive to traditional therapies and treated effectively with a combination of
interferon and ribavirin.
 2014 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious
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Acquired aplastic anemia (AA) is typically classiﬁed as severe,
very severe, or non-severe. The severe type is characterized by
bone marrow cellularity <25% or 25–50% with <30% residual
hematopoietic cells and two out of three of the following:
neutrophils <0.5  109/l, platelets <20  109/l, reticulocytes
<20  109/l. In very severe AA, neutrophils are <0.2  109/l.
Non-severe AA does not fulﬁll the criteria for severe or very severe
AA. Affected patients are at risk of bacterial, fungal, and viral
infections.
Genital warts caused by a sexually transmitted infection with
human papillomavirus (HPV) are common in the general popula-
tion and are very frequent in immunocompromised patients. The
disease has many physical and psychosexual effects and can
progress to neoplasia. More than 100 different serotypes of HPV are
known and about 30 show a strong tropism for the mucous
membranes of the genitourinary tract. Prominent among these are
low-risk serotypes HPV6 and HPV11, which are mainly related to       
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possible extension to the perianal region) and high-risk serotypes
HPVs 16, 18, 31, 51, and 52, which are involved above all in cervical
disease.
Both the innate and adaptive immune responses play a critical
role in HPV infection. This role is supported by the observation that
both immunodeﬁciencies due to an alteration in innate immunity
(such as WHIM (Warts, Hypogammaglobulinemia, Infections and
Myelokathexis), epidermodysplasia verruciformis, and major
histocompatibility complex (MHC) class II deﬁciency) and
immunodeﬁciencies linked to an alteration in adaptive immunity
(CD4 idiopathic lymphocytopenia and DOCK 8 immunodeﬁciency)
increase the risk of persistent HPV infections. HPV has evolved
several mechanisms to evade innate immunity, such as interfering
with the TLR signaling pathway leading to suppression of type I
interferon production,1 and the interplay of the host immune
system with the HPV immune evasion mechanisms determines
whether an HPV infection is cleared or becomes persistent, even in
patients who are not immunocompromised; some women show
clearance within weeks and others after 1–2 years.2
The choice of therapy for genital warts depends on the
morphology and extension of the lesion, and also on the possible
co-morbidities; it should be decided upon by mutual agreement
between the physician and the patient. In Europe, guidelines for
the treatment of anogenital warts have recently been published,
and it has been emphasized that only surgery has successfulociety for Infectious Diseases. Open access under CC BY-NC-ND license.
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With the current algorithm, podophyllotoxin, imiquimod, or
sinecatechins are used as home therapies; provider-administered
therapies include electrosurgery, excision/curettage, or laser
therapy in a single session, or multiple sessions of cryotherapy
or trichloroacetic acid. Patients are usually referred to a specialist
for special circumstances, i.e., those who are immunosuppressed
or pregnant, and children. It should be noted that the expense of
the therapy increases when traditional treatment is ineffective, as
in our immunocompromised patient. The cost of local treatment is
around 60 Euros with podophyllin and 250 Euros with imiquimod.
A cryotherapy session costs around 70–80 Euros and a laser or
electrocoagulation session costs approximately 200–300 Euros.
The total cost of the treatment with subcutaneous interferon a2b
and oral ribavirin was about 3000 Euros in our patient.
2. Case report
The case patient had suffered from non-severe AA since the age
of 11 years. On ﬁrst bone marrow biopsy, cellularity had been
approximately 30% and this did not present any signiﬁcant change
over the years. The patient had never been treated and had
received no transfusion. Her blood count revealed platelets
<100  109/l only occasionally (never <50  109/l), neutrophils
on average between 1.0 and 1.5  109/l (never <0.5  109/l), and
hemoglobin between 8.5 and 12 g/dl. CD4+ T cells were 850/ml at
her ﬁrst admission to our department. The patient had become
sexually active at the age of 16 years and sometimes did not haveFigure 1. Therapies administered and results obtained. (A) Genital warts before treatme
Genitals at 30 weeks after the end of therapy.safe sex. Just before the appearance of genital disease she had
started a sexually exclusive relationship and her partner did not
suffer from genital warts. At the age of 22 years (end of June 2011),
she exhibited warts on the vulva, the clitoral hood, and around the
anus. Her CD4+ T cells were 350/ml at that time.
Genotyping of the patient’s HPV was repeated after 4 months:
the ﬁrst swab was vulva-vaginal and the second one cervical. The
Linear Array HPV Genotyping Test (Roche, Basil, Switzerland) was
used. On both occasions three genotypes were identiﬁed, two of
which are high-risk (HPV31 and HPV52) and one low-risk (HPV6)
for cervical cancer. However, assigning the HPV genotype detected
in a lesion as the causative agent of that lesion is problematic.
Imiquimod was administered ﬁrst, as topical treatment;
however after an initial improvement, the lesions were still
present 3 months into therapy. The patient was then treated with
cryotherapy, but after an initial improvement there was a
recurrence of the lesions. Approximately 6 months from onset,
the warts were removed surgically through diathermocoagulation.
The pathological diagnosis was ﬂorid condyloma with no evidence
of malignancy. Two months after surgery the patient developed
intense pain radiating to the posterior left thigh due to the
presence of new lesions. A colonoscopy was performed and
multiple warts were found up to the pectinate line. The severe pain
and discomfort after ﬁrst-line and surgical treatment led us to
consider other therapeutic options. Mesalazine 500 mg supposi-
tories (two per day), a topical steroid, and an oral antibiotic
(amoxicillin/clavulanic acid) were administered for 4 weeks, but
there was only a slight improvement in pain symptoms.nt with interferon alpha and ribavirin. (B) Genitals after 8 weeks of treatment. (C)
C. Mosa et al. / International Journal of Infectious Diseases 23 (2014) 25–27 27Approximately 10 months after the warts had appeared, hyper-
emic edema with a perianal ulcerative lesion on the left side of the
rectal wall appeared (Figure 1A). Local therapy with potassium
permanganate and a local antibiotic were administered. In
addition, since the absolute neutrophil count was on average
0.8  109/l, granulocyte colony-stimulating factor (GCSF) was
administered at an initial dosage of 5 mg/kg daily. By modulating
the doses of GCSF, we maintained the neutrophils stable above
1.5  109/l. With this treatment there was an improvement in the
inﬂammation and a reduction in the ulcer, but the warts appeared
unchanged. In June 2012 the patient started interferon a2b at a
dosage of 10 million IU subcutaneously once per week and oral
ribavirin 400 mg twice per day. During the interferon therapy the
patient manifested the anticipated inﬂuenza-like symptoms. The
response to this treatment was dramatic: the patient noticed that
the warts were noticeably smaller after 2 weeks, and after 8 weeks
they had disappeared completely (Figure 1B). She underwent
magnetic resonance imaging of the rectal canal and perianal area,
which showed the presence of a trans-sphincter ﬁstula, with an
opening in the rear area of the left labium majus. The ﬁstula was
treated successfully with surgery. Due to concern about a possible
relapse of the HPV infection, the antiviral therapy was also
administered for 4 weeks following the clinical elimination of all of
the warts, for a total duration of 12 weeks. At 4 weeks after the end
of therapy with interferon/ribavirin, the patient’s CD4+ count was
150/ml. Complete remission was also conﬁrmed 30 weeks after the
end of therapy (Figure 1C).
3. Discussion
Patients with AA are at high risk of infections. To date, no case
reports of disseminated papillomavirus in patients with aplastic
anemia treated with interferon and ribavirin have been published.
Our patient suffered from a non-severe AA and had never
experienced a serious infection, except for a subcutaneous abscess
of the neck that had occurred 5 years before the appearance of the
warts. Nevertheless, her history was complicated by a dramaticallyprogressing papillomatosis that responded poorly to standard
therapy, as usual in immunocompromised patients. Moreover, at
the appearance of the infection, her CD4+ T cell count had fallen
below 350/ml, which could explain the failure to eliminate the
virus. We decided to use interferon and ribavirin on the basis of
previous reports in which the combination of these drugs proved to
be effective in the resolution of extensive plantar warts3 and
disseminated HPV infection.4 Moreover ribavirin, a synthetic
nucleoside that is active against many viral DNA and RNA, has been
reported to be effective for the treatment of juvenile laryngeal
papillomatosis.5
The association of these two drugs was found to be highly
effective in our patient, in spite of low CD4+ counts. Thus we
suggest that this therapy should be considered in immunocom-
promised patients and probably also in cases of diffuse and/or
complicated papillomatosis unresponsive to ﬁrst- and second-line
treatments.
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